全文获取类型
收费全文 | 2448631篇 |
免费 | 172254篇 |
国内免费 | 4813篇 |
专业分类
耳鼻咽喉 | 33015篇 |
儿科学 | 80100篇 |
妇产科学 | 67018篇 |
基础医学 | 348832篇 |
口腔科学 | 70959篇 |
临床医学 | 221211篇 |
内科学 | 469647篇 |
皮肤病学 | 55741篇 |
神经病学 | 189594篇 |
特种医学 | 93427篇 |
外国民族医学 | 437篇 |
外科学 | 369654篇 |
综合类 | 53892篇 |
现状与发展 | 5篇 |
一般理论 | 758篇 |
预防医学 | 179924篇 |
眼科学 | 57954篇 |
药学 | 184984篇 |
13篇 | |
中国医学 | 6180篇 |
肿瘤学 | 142353篇 |
出版年
2021年 | 18353篇 |
2019年 | 18990篇 |
2018年 | 27559篇 |
2017年 | 21177篇 |
2016年 | 23532篇 |
2015年 | 26626篇 |
2014年 | 36750篇 |
2013年 | 53804篇 |
2012年 | 74177篇 |
2011年 | 78187篇 |
2010年 | 46363篇 |
2009年 | 43320篇 |
2008年 | 72436篇 |
2007年 | 77305篇 |
2006年 | 77947篇 |
2005年 | 74509篇 |
2004年 | 71668篇 |
2003年 | 68458篇 |
2002年 | 65913篇 |
2001年 | 127885篇 |
2000年 | 130899篇 |
1999年 | 108554篇 |
1998年 | 28398篇 |
1997年 | 24853篇 |
1996年 | 24930篇 |
1995年 | 23825篇 |
1994年 | 21745篇 |
1993年 | 20323篇 |
1992年 | 81990篇 |
1991年 | 79076篇 |
1990年 | 76854篇 |
1989年 | 73760篇 |
1988年 | 67051篇 |
1987年 | 65335篇 |
1986年 | 61747篇 |
1985年 | 58529篇 |
1984年 | 42857篇 |
1983年 | 36479篇 |
1982年 | 20482篇 |
1979年 | 38163篇 |
1978年 | 26240篇 |
1977年 | 22828篇 |
1976年 | 20710篇 |
1975年 | 22521篇 |
1974年 | 26906篇 |
1973年 | 25929篇 |
1972年 | 24216篇 |
1971年 | 22606篇 |
1970年 | 20904篇 |
1969年 | 19770篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
161.
Matthew J Matasar Ellen K Ritchie Nathan Consedine Carol Magai Alfred I Neugut 《European journal of cancer prevention》2006,15(4):367-370
Despite significant improvements in the prognosis of acute promyelocytic leukemia brought about by therapeutic advances, understanding of the epidemiology of acute promyelocytic leukemia remains limited. Earlier reports have suggested that Hispanics may have an increased incidence of acute promyelocytic leukemia, but no systematic analysis of national data has yet been reported. We performed a retrospective cohort study, using data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute from 1992-2001 in order to compare leukemia incidence rates as a function of race and ethnicity. We identified 709 cases of acute promyelocytic leukemia and analyzed incidence rates by race and sex. Hispanics were not found to have greater lifetime incidence rates than whites, with an incidence relative rate (IRR) of 0.86 that of whites (P=0.17). The age distribution among Hispanics was significantly different from non-Hispanic whites, with greater incidence rates for children ages 1-19 years (IRR=1.9, P=0.02) and adult ages 20-44 years (IRR=1.6, P=0.004). Blacks had lower lifetime incidence rates than non-Hispanic whites (IRR=0.75, P=0.04), Hispanics (IRR=0.64, P=0.007), and Asians (IRR=0.67, P=0.03). Asians did not differ from non-Hispanic whites in lifetime or age-specific incidence rates. These results indicate that while US Hispanics do not have greater lifetime incidence rates of acute promyelocytic leukemia, blacks have lower incidence rates of acute promyelocytic leukemia than Hispanics, non-Hispanic whites, and Asians. 相似文献
162.
Caterina Proto Daniela Romualdi Rosa Maria Cento Rosario S Spada Giuseppina Di Mento Raffaele Ferri Antonio Lanzone 《Gynecological endocrinology》2006,22(4):213-218
BACKGROUND: In the central nervous system, several neuropeptides are believed to be involved in the pathophysiology of Alzheimer's disease (AD). Indeed, previous studies have documented that glucagon-like peptide 1 (GLP-1) possesses neurotropic properties and can reduce amyloid-beta peptide levels in the brain in vivo. Moreover, the concentrations of neuropeptide Y (NPY) seem to be altered in the cerebrospinal fluid of patients with AD and in subjects with major depression. Finally, among the modifications induced by aging, a dysregulation of the ghrelin-growth hormone (GH) system has been reported. METHODS: We investigated the plasma concentrations of these neuropeptides in 14 subjects with AD. Data obtained from these patients were compared with data from an age- and weight-matched healthy group. RESULTS: No significant differences were found between the two groups in relation to plasma levels of GLP-1, NPY, ghrelin and GH. Peripheral NPY concentrations were positively correlated with ghrelin levels in both groups, and with plasma GLP-1 concentration only in controls. CONCLUSION: On the basis of our results, peripheral levels of these neuropeptides seem not to serve as biochemical markers of AD. 相似文献
163.
164.
165.
We present evidence to show that monoclonal antibodies to estrogen receptors (ER) in solid phase recognize the secondary estrogen binding sites with moderate to low affinity for estradiol (E2). An excellent quantitative agreement was found in five cytosols between the ER values obtained by the enzyme immunoassay (ER-EIA) and the amount of secondary estrogen binding sites measured by the assay involving dextran-coated charcoal (Clin Chem 1986;32:1496). The immunoreactive protein recognized by the antibody-coated beads, when allowed to react with ER(+) cytosols, is shown to bind [3H]estradiol only when the ligand concentration exceeds 8 nmol/L. Further biochemical and functional characterization of the immunoreactive protein is required to establish similarities/dissimilarities between this protein, high-affinity Type I ER sites, and the secondary sites such as Type II sites. 相似文献
166.
J?rg Müller Klaus Seppi Nadia Stefanova Werner Poewe Irene Litvan Gregor K Wenning 《Movement disorders》2002,17(5):1041-1045
The frequency and pathophysiology of freezing of gait (FoG) in atypical parkinsonism is unknown. We analysed the frequency of FoG in postmortem-confirmed atypical parkinsonian disorders (APD) comprising corticobasal degeneration (CBD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Sixty-six patients with pathologically confirmed APD (CBD, n = 13; DLB, n = 14; MSA, n = 15; PSP, n = 24) formed the basis for a multicenter clinicopathological study. Clinical features at first and last clinical visit were abstracted from patient records on standardized forms following strict instructions. At the first visit (median 36 months after symptom onset), 24% of APD had FoG (CBD, 8%; DLB, 21%; PSP, 25%; MSA, 40%). Logistic regression analysis showed a significant association of FoG and urinary incontinence (P = 0.04) at first visit. At last visit, 47% of APD had FoG (CBD, 25%; PSP, 53%; DLB, 54%; MSA, 54%). Clinicopathological correlation based on routine postmortem examination failed to identify a consistent neuropathological substrate of FoG. This study demonstrates that (1) FoG is common in APD, and (2) urinary incontinence is significantly associated with FoG in these disorders. Whether FoG and urinary incontinence share similar neuropathological substrates remains to be determined by future studies. 相似文献
167.
Summary Experimental data suggest that multidrug resistance in cancer may be overcome by using an increased dose of anticancer agent(s) in combination with a resistance-modifying agent (RMA). We studied the pharmacokinetics and metabolism of both epirubicin (EPI) and verapamil (VPL) to explore the possible pharmacokinetic interactions between these two drugs. Ten patients with advanced breast cancer were given EPI (40 mg/m2 in a daily i.v. bolus for 3 consecutive days), and five of them also received VPL (4×120 mg/daily p.o. for 4 consecutive days). The data indicated a significant interaction between these two drugs that affected their metabolism. The areas under the concentration-time curves (AUC) obtained for epirubicin glucuronide, epirubicinol glucuronide, and both of the 7-deoxy-aglycones were higher in the EPI+VPL group as compared with the EPI group. The AUC, terminal half-life, mean residence time, volume of distribution at steady state, and plasma clearance of EPI alone as compared with EPI+VPL did not differ significantly. These results suggest either an induction of enzymes necessary for drug metabolism or an increase in the liver blood flow, resulting in an enhanced generation of metabolites with time or in an inhibition of excretion processes. Comparisons of the AUC values obtained for EPI and its metabolites after the first, second, and third injections of EPI revealed a cumulative effect for the metabolites that was more pronounced in the EPI+VPL group, being significant (P<0.05) for epirubicin glucuronide in both treatment groups and for epirubicinol glucuronide in the EPI+VPL group. Maximal concentrations of VPL and nor-VPL reached 705±473 and 308±122 ng/ml, respectively, with the steady-state concentrations being 265±42 ng/ml for VPL and 180±12 ng/ml for nor-VPL.This study was supported by the Erich und Gertrud Roggenbuck-Stiftung zur Förderung der Krebsforschung (Hamburg). The anthracycline metabolites were kindly provided by Dr. A. Suarato (Farmitalia, Milano, Italy); nor verapamil was provided by Dr. Traugott (Knoll, Ludwigshafen, Germany) 相似文献
168.
A mechanistic QSAR study on N-nitrosamines (NA) was performed with the aid of the semiempirical MINDO/3 method. Both the chemical reactivity and the transport in biological medium were taken into account. The parent NA molecules and their first reaction intermediates in the metabolic activation pathway were examined for possible determinants of the relative carcinogenic potency. The correlations found support the previous suggestions concerning the metabolic C alpha radical hydroxylation of NA. The role of transport properties in the early stage of NA biotransformation was also demonstrated. 相似文献
169.
S Hummel J Slapke 《Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete》1988,43(12):319-323
In any case of acute bronchoconstriction the possibility of an adverse reaction to a drug should be considered. In many of such side reactions no allergic mechanism can be detected. Therefore, they are included into the category of pseudoallergic reactions (PAR). The clinically most important form of drug-induced bronchial asthma, analgesics asthma, belongs to this PAR group. A further risk for asthmatics are intravenous applications of contrast-media for roentgenography which in about 15% induce a severe, sometimes life-threatening pseudo-allergic adverse reaction. In asthmatics, the application of any beta-receptor blocking agents and also the use of parasympathicotonic eye drops for treatment of glaucoma are contraindicated. Paradoxical bronchial constriction following application of antiasthmatics are preponderantly caused by locally irritative actions, less frequently by genuine allergic phenomena or additive intolerance. The most reliable prophylaxis against drug-induced bronchial asthma consists in strong avoidance of all derivatives possibly capable to trigger any intolerance. A respective warning should entered into the emergency passport. 相似文献